Search in biosurfit Start writing...
18th April 2022

biosurfit signs strategic partnership with FIND, the global alliance for diagnostics

biosurfit signs strategic partnership with FIND, the global alliance for diagnostics
to accelerate commercialization of haematology solutions to low- and middle-income countries

Azambuja, Portugal, April 2022 – biosurfit SA ("biosurfit”), the in vitro point-of-care (PoC) diagnostics company, announces a strategic partnership with FIND, the global alliance for diagnostics, a non-profit organization, to increase access to critical haematology parameters, by accelerating the availability of point-of-care haematology analysers in to low- and middle-income countries (LMICs).

Haematology tests are considered as fundamental tools for health systems. Extreme environmental conditions, certification processes and decentralized environments, are the main challenges for implementing point-of-care haematology solutions in developing countries. The investment fund from FIND will enable biosurfit to allocate resources to test and adapt the existing spinit® Blood Count product (the spinit® BC disposable disc and the spinit® instrument) to respond to the unmet need of haematology point of care solutions making it more accessible, in those countries with low financial resources and extreme environmental conditions.

Rosa Santos, Chief Executive Officer of biosurfit said: "We are very honoured to work with FIND to bring advanced blood cell counting solutions to low- and middle-income countries. We are very excited with the prospects of fine-tuning our spinit® product to be validated for more extreme ambient conditions and further deployment in the field. Point of Care testing is an extremely important tool in healthcare and in less developed countries. We are very proud and happy to work with FIND to bring this vision into real life.”

"When a patient presents at a clinic with a fever, it is essential to know very quickly whether the cause is severe or not, so that the urgency of the situation can be established, and appropriate treatment initiated. Basic tools that can be used at the point of care to assess complete blood count and guide triage are generally not suitable for use in low-resource settings, as for example they require very low operating temperatures. FIND is pleased to support the adaptation of biosurfit established haematology technology as part of a project designed to help enable rapid, comprehensive blood analysis in clinics across low- and middle-income countries – to guide care and save lives,” said Marta Fernández Suárez, Chief Technology Officer at FIND.

For enquiries please contact:
biosurfit SA| Marketing & Communications
Tel : +351 218 860 169

Failed to load the Page Fonts We apologize, but the user experience may not be the best! Got it